期刊簡介預計審稿時間： 12 Weeks

The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.

將醫(yī)學上的新發(fā)現(xiàn)轉(zhuǎn)化為臨床常規(guī)從來都不是一件容易的事。在上個世紀下半葉，由于化學、生物化學和藥理學的進步，我們看到了大量藥物和設(shè)備的開發(fā)和應用，這些藥物和設(shè)備旨在治療癥狀、阻斷不必要的途徑，并在傳染病的情況下對抗導致疾病的微生物。然而，今天，我們正面臨著病理和疾病治療方法的巨大變化。事實上，現(xiàn)在和未來十年的挑戰(zhàn)是完全恢復患病生物體的生理狀態(tài)，并在組織和器官受到嚴重影響以至于治療不能局限于抑制癥狀或修復損傷時完全再生組織和器官。這得益于基礎(chǔ)細胞和分子生物學的重大發(fā)展，包括干細胞科學、生長因子傳遞、基因分離和轉(zhuǎn)染，生物工程和納米技術(shù)的進步，包括新生物材料的開發(fā)、生物制造技術(shù)和生物反應器的使用，以及診斷工具和細胞、組織和器官成像的巨大改進。

在當今世界，加強多學科專家之間的交流，促進聯(lián)合項目以及科學家、工程師、行業(yè)人士、監(jiān)管機構(gòu)和醫(yī)生之間的密切合作，是成功開發(fā)和臨床應用新生物療法或創(chuàng)新設(shè)備（涉及生物材料、細胞和/或生物活性分子的集體使用）的絕對要求。“生物工程和生物技術(shù)前沿”希望成為參與這一過程的所有人的一個論壇，彌合基礎(chǔ)科學發(fā)現(xiàn)與其臨床應用之間經(jīng)常存在的差距。

《Frontiers In Bioengineering And Biotechnology》(生物工程和生物技術(shù)前沿)編輯部通訊方式為AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015。如果您需要協(xié)助投稿或潤稿服務，您可以咨詢我們的客服老師。我們專注于期刊投稿服務十年，熟悉發(fā)表政策，可為您提供一對一投稿指導，避免您在投稿時頻繁碰壁，節(jié)省您的寶貴時間，有效提升發(fā)表機率，確保SCI檢索（檢索不了全額退款）。我們視信譽為生命，多方面確保文章安全保密，在任何情況下都不會泄露您的個人信息或稿件內(nèi)容。